



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 11:48  
**Last Report Issued** 08/05/2015 07:53

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 1055B-POS  
**Patient ID** 1055B-POS  
**Chain** 15001959  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 15001959  
**Received** 08/04/2015 06:25

**Sample ID** 15001959-001  
**Matrix** Blood  
**Patient Name** 1055B-POS  
**Patient ID** 1055B-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**1055B Celecoxib, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Celecoxib	50	ng/mL	20	
Synonym(s): Celebrex®				

Single oral doses of 100 and 200 mg in 4 subjects resulted in average peak plasma concentrations of 362 and 797 ng/mL, respectively, at times of 1.4 and 1.8 hours. Elimination half-lives in rapid and slow metabolizers averaged 14 and 52 hours, respectively.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.